News
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
ESSA Pharma to Participate in Upcoming Investor Conferences
ESSA Pharma Inc. Announce the Delisting from the TSX-V
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences